Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mengqiu Tang, Chao Song, Yaowen Zhang, Xiaoyu Xu, Chen Wang, Zhanchun Zhang, Tian Chen
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Triglycerides (TG) Total cholesterol (TC) Low density lipoprotein (LDL) High density lipoprotein (HDL) Anlotinib Non-small cell lung cancer (NSCLC) Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/6fe58de71bfe4ffa81cf84773b662752
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6fe58de71bfe4ffa81cf84773b662752
record_format	dspace
spelling	oai:doaj.org-article:6fe58de71bfe4ffa81cf84773b6627522021-11-21T12:40:36ZLevels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib10.1186/s12944-021-01596-51476-511Xhttps://doaj.org/article/6fe58de71bfe4ffa81cf84773b6627522021-11-01T00:00:00Zhttps://doi.org/10.1186/s12944-021-01596-5https://doaj.org/toc/1476-511XAbstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Although numerous inflammatory biomarkers have been shown to play vital roles in treatment, the clinical significance of blood lipid levels before treatment has not been evaluated. Here, this research aims to explore the relationship between blood lipids and efficacy of anlotinib, with a view of generating insights to guide future development of convenient and individualized treatment therapies. Methods This study analyzed basal blood lipids levels, including triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL), among other variables before treatment, in 137 patients with advanced NSCLC who received anlotinib as third or further-line treatment at the Ningbo Medical Center Lihuili Hospital, between July 2018 and December 2020. We determined the best cut off value for predicting treatment responses, generated survival curves using the Kaplan–Meier method, then applied univariate and multivariate Cox regression analyses to assess predictors of survival. Results The entire study population recorded median progression-free survival (PFS) and overall survival (OS) of 4 (95% CI 3.142–4.858) and 8.3 (95% CI 6.843–9.757) months, respectively. Researchers observed statistically significant differences across subgroups, between blood lipid indexes with different efficacies, except in the HDL subgroup. The low disease control rate (DCR) was associated with significantly elevated TG, TC and LDL levels (P = 0.000). Multivariate analysis demonstrated that elevated TC and LDL levels were independently associated with poor PFS or OS (P ≤ 0.003). Then, we established a prediction model, and set high TC or high LDL as the risk factor, respectively. There were significant differences in PFS (p = 0.000) and OS (p = 0.012) between 0 and ≥ 1 scores. Conclusions Prior to anlotinib therapy, TC and LDL levels, are independent prognostic indicators for patients with advanced NSCLC treated with this drug as a third or further-line treatment option. In addition, a risk score of 0 was attributed to a combination of low TC and low LDL, and these patients were exhibited excellent efficacies and survival rates.Mengqiu TangChao SongYaowen ZhangXiaoyu XuChen WangZhanchun ZhangTian ChenBMCarticleTriglycerides (TG)Total cholesterol (TC)Low density lipoprotein (LDL)High density lipoprotein (HDL)AnlotinibNon-small cell lung cancer (NSCLC)Nutritional diseases. Deficiency diseasesRC620-627ENLipids in Health and Disease, Vol 20, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Triglycerides (TG) Total cholesterol (TC) Low density lipoprotein (LDL) High density lipoprotein (HDL) Anlotinib Non-small cell lung cancer (NSCLC) Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	Triglycerides (TG) Total cholesterol (TC) Low density lipoprotein (LDL) High density lipoprotein (HDL) Anlotinib Non-small cell lung cancer (NSCLC) Nutritional diseases. Deficiency diseases RC620-627 Mengqiu Tang Chao Song Yaowen Zhang Xiaoyu Xu Chen Wang Zhanchun Zhang Tian Chen Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
description	Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Although numerous inflammatory biomarkers have been shown to play vital roles in treatment, the clinical significance of blood lipid levels before treatment has not been evaluated. Here, this research aims to explore the relationship between blood lipids and efficacy of anlotinib, with a view of generating insights to guide future development of convenient and individualized treatment therapies. Methods This study analyzed basal blood lipids levels, including triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL), among other variables before treatment, in 137 patients with advanced NSCLC who received anlotinib as third or further-line treatment at the Ningbo Medical Center Lihuili Hospital, between July 2018 and December 2020. We determined the best cut off value for predicting treatment responses, generated survival curves using the Kaplan–Meier method, then applied univariate and multivariate Cox regression analyses to assess predictors of survival. Results The entire study population recorded median progression-free survival (PFS) and overall survival (OS) of 4 (95% CI 3.142–4.858) and 8.3 (95% CI 6.843–9.757) months, respectively. Researchers observed statistically significant differences across subgroups, between blood lipid indexes with different efficacies, except in the HDL subgroup. The low disease control rate (DCR) was associated with significantly elevated TG, TC and LDL levels (P = 0.000). Multivariate analysis demonstrated that elevated TC and LDL levels were independently associated with poor PFS or OS (P ≤ 0.003). Then, we established a prediction model, and set high TC or high LDL as the risk factor, respectively. There were significant differences in PFS (p = 0.000) and OS (p = 0.012) between 0 and ≥ 1 scores. Conclusions Prior to anlotinib therapy, TC and LDL levels, are independent prognostic indicators for patients with advanced NSCLC treated with this drug as a third or further-line treatment option. In addition, a risk score of 0 was attributed to a combination of low TC and low LDL, and these patients were exhibited excellent efficacies and survival rates.
format	article
author	Mengqiu Tang Chao Song Yaowen Zhang Xiaoyu Xu Chen Wang Zhanchun Zhang Tian Chen
author_facet	Mengqiu Tang Chao Song Yaowen Zhang Xiaoyu Xu Chen Wang Zhanchun Zhang Tian Chen
author_sort	Mengqiu Tang
title	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
title_short	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
title_full	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
title_fullStr	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
title_full_unstemmed	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
title_sort	levels of pretreatment blood lipids are prognostic factors in advanced nsclc patients treated with anlotinib
publisher	BMC
publishDate	2021
url	https://doaj.org/article/6fe58de71bfe4ffa81cf84773b662752
work_keys_str_mv	AT mengqiutang levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib AT chaosong levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib AT yaowenzhang levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib AT xiaoyuxu levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib AT chenwang levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib AT zhanchunzhang levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib AT tianchen levelsofpretreatmentbloodlipidsareprognosticfactorsinadvancednsclcpatientstreatedwithanlotinib
_version_	1718418890057318400

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

Ejemplares similares